Ajovy (Fremanezumab-vfrm) for Migraine | MyMigraineTeam

Connect with others who understand.

sign up Log in
About MyMigraineTeam
Powered By

Ajovy is approved by the Food and Drug Administration (FDA) to prevent migraine in adults. Ajovy is also referred to by its drug name, Fremanezumab-vfrm.

Ajovy is a biologic drug – a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Ajovy is also a member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonists. Ajovy is believed to work by interfering with CGRP, a substance that dilates blood vessels and contributes to pain signals and inflammation.

How do I take it?
Prescribing information states that Ajovy is administered as a subcutaneous injection once a month or every three months.

Ajovy comes in prefilled, single-dose syringes.

Side effects
The FDA-approved label for Ajovy lists injection site reactions as a common side effect.

Because Ajovy is a new drug, its long-term effects are not yet known.

For more details about this treatment, visit:

Ajovy.com – Teva

Ajovy Approved by FDA as Second CGRP Blocker for Migraine Prevention – Migraine.com

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in